Combined differentiating therapy for myelodysplastic syndromes: A phase II study
1996; Elsevier BV; Volume: 20; Issue: 10 Linguagem: Inglês
10.1016/0145-2126(95)00156-5
ISSN1873-5835
AutoresDario Ferrero, Benedetto Bruno, Patrizia Pregno, Silvia De Stefani, E Larizza, G Ciravegna, Annalisa Luraschi, Guido Vietti-Ramus, Piercarla Schinco, Mario Bazzan, E Gallo, Alessandro Pileri,
Tópico(s)Hematopoietic Stem Cell Transplantation
ResumoAn in vitro synergism between different inducers of AML cell differentiation has been previously observed. Therefore, we treated 53 myelodysplastic (MDS) patients with a low dose combination of cis-retinoic acid (cRA, 20–40 mg/day) and 1,25 α(OH)2 cholecalciferol [(OH)2D3, 1–1.5μg/day] ± intermittent 6-thioguanine (30 mg/m2/day). The latter was reserved for patients with bone marrow (BM) blast excess (⩾5%). The treatment was well tolerated, without major toxicity. Among 25 patients with BM blasts less than 5%, we observed one complete, eight partial and four minor responses (response rate 52%) with a median response duration of 8 months (2+−24). Median survival, which did not correlate with response, is projected at 76 months. Thirty-one patients with BM blast excess (⩾ 5%), including three of the previous group who progressed to refractory anemia with excess of blasts (RAEB), were treated with the three-drug protocol. One complete, 12 partial and six minor responses were obtained (response rate 61%) with a median response duration of 6 months (2−29+). A significant difference in survival (P < 0.005) was observed between the 19 responders (median 25 months) and the 12 non-responders (median 9 months). A reduction in the transfusion need was observed in 41% of the transfusion-dependent patients with blast excess and in 53% of those without blast excess. Therefore, combined differentiating therapy seems more effective than previously reported single agent treatments and should be considered for a larger randomized study to assess its actual impact on survival of MDS patients.
Referência(s)